293 related articles for article (PubMed ID: 31362662)
1. A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report.
Dastoli S; Iannone LF; Bennardo L; Silvestri M; Palleria C; Nisticò SP; De Sarro G; Russo E
Curr Drug Saf; 2020; 15(1):69-72. PubMed ID: 31362662
[TBL] [Abstract][Full Text] [Related]
2. A Rare Case of Drug-induced Erectile Dysfunction with Adalimumab and Certolizumab Solved after Switch to Ustekinumab in a Crohn's Disease Patient.
Hidalgo-Rios S; Alonso-Moreno M; Iserte JT; Herrera-Justiniano JM
Curr Drug Saf; 2023; 18(3):374-378. PubMed ID: 35507800
[TBL] [Abstract][Full Text] [Related]
3. IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience.
Sherman S; Solomon Cohen E; Amitay-Laish I; Hodak E; Pavlovsky L
Acta Derm Venereol; 2019 Jul; 99(9):769-773. PubMed ID: 31017250
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
5. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
Egeberg A; Bryld LE; Skov L
J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.
Amschler K; Phillip S; Mohr J; Wilsmann-Theis D; Poortinga S; Gerdes S; Mössner R
Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155021
[TBL] [Abstract][Full Text] [Related]
7. Anti-IL17 therapies for psoriasis.
Silfvast-Kaiser A; Paek SY; Menter A
Expert Opin Biol Ther; 2019 Jan; 19(1):45-54. PubMed ID: 30500317
[TBL] [Abstract][Full Text] [Related]
8. Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab.
Blauvelt A; Shi N; Burge R; Malatestinic WN; Lin CY; Lew CR; Zimmerman NM; Goldblum OM; Zhu B; Murage MJ
J Am Acad Dermatol; 2020 Apr; 82(4):927-935. PubMed ID: 31712178
[TBL] [Abstract][Full Text] [Related]
9. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
10. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
11. A Randomized Controlled Ixekizumab Vs Secukinumab Trial to Study the Impact on Sexual Activity in Adult Patients with Genital Psoriasis.
AlMutairi N; Eassa BI
Expert Opin Biol Ther; 2021 Feb; 21(2):297-298. PubMed ID: 33115285
[No Abstract] [Full Text] [Related]
12. Comparison of two-year treatment adherence, persistence, discontinuation, reinitiation, and switching between psoriasis patients treated with ixekizumab or secukinumab in real-world settings.
Blauvelt A; Shi N; Somani N; Burge R; Zhu B; Ridenour TL; Lew CR; Zimmerman NM; Atiya B; Murage MJ
J Am Acad Dermatol; 2022 Mar; 86(3):581-589. PubMed ID: 34252464
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
Georgakopoulos JR; Phung M; Ighani A; Yeung J
J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
[No Abstract] [Full Text] [Related]
16. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
Pizzicato LN; Vadhariya A; Birt J; Ketkar AG; Bolce R; Grabner M; Pepe RS; Walsh JA
J Manag Care Spec Pharm; 2023 Jan; 29(1):24-35. PubMed ID: 36318701
[No Abstract] [Full Text] [Related]
17. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
Caldarola G; Pirro F; Di Stefani A; Talamonti M; Galluzzo M; D'Adamio S; Magnano M; Bernardini N; Malagoli P; Bardazzi F; Potenza C; Bianchi L; Peris K; De Simone C
Expert Opin Biol Ther; 2020 Jun; 20(6):665-672. PubMed ID: 32045273
[No Abstract] [Full Text] [Related]
18. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
Deza G; Notario J; Lopez-Ferrer A; Vilarrasa E; Ferran M; Del Alcazar E; Carrascosa JM; Corral M; Salleras M; Ribera M; Puig L; Pujol RM; Vidal D; Gallardo F
J Eur Acad Dermatol Venereol; 2019 Mar; 33(3):553-559. PubMed ID: 30317679
[TBL] [Abstract][Full Text] [Related]
19. Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab.
Warren RB; Brnabic A; Saure D; Langley RG; See K; Wu JJ; Schacht A; Mallbris L; Nast A
Br J Dermatol; 2018 May; 178(5):1064-1071. PubMed ID: 29171861
[TBL] [Abstract][Full Text] [Related]
20. Ixekizumab (Taltz)--a second IL-17A inhibitor for psoriasis.
Med Lett Drugs Ther; 2016 May; 58(1494):59-60. PubMed ID: 27148922
[No Abstract] [Full Text] [Related]
[Next] [New Search]
